Browse studies

Find your next paid study

499 recruiting studies matching your filters

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients With Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment With B-cell Depletion Therapy ("PROTECT")

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Pa…

HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions+1 more

Estimated

~$10 – $8,750

OctapharmaNCT07220915

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in parti…

Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection Recurrence+7 more

Estimated

~$10 – $8,750

Vedanta Biosciences, Inc.NCT06237452

Phase 4

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (ONLY ONCE)

The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections aroun…

Pleural Infection BacterialPleural InfectionsPleural Infections and Inflammations+5 more

Estimated

~$10 – $6,250

University of North Carolina, Chapel HillNCT07095361

Phase 3

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART

This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and a…

HIV Infections

Estimated

~$10 – $7,500

ViiV HealthcareNCT07650916

Phase 1

Phase 1, Open-Label, Single Arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants From 2 to Less Than 12 Years of Age With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis With Antibiotics

The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized p…

Urinary Tract Infections

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07371429

Cryptococcosis in Previously Healthy Adults

The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) G…

Cryptococcal InfectionCryptococcal PneumoniaPulmonary Cryptococcosis+2 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001352

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome…

InfectionsPneumoniaImmune System Diseases+2 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00006150

Observational

A Prospective Randomized Study of Surgical Site Infection After Linear Repair With or Without Cyanoacrylate Skin Adhesive Following Mohs Micrographic Surgery and Wide Local Excision

This study will compare surgical site infection after linear repair with or without cyanoacrylate skin adhesive following Mohs micrographic surgery or wide loc…

Surgical Site InfectionSkin CancerWound Healing

Estimated

~$10 – $6,250

University of MinnesotaNCT07844681

Phase 1

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chro…

Hepatitis B Virus Infection

Estimated

~$10 – $8,750

GigaGen, Inc.NCT07024641

Phase 4

An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter

This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric …

Catheter-Related Infections

Estimated

~$10 – $8,750

CorMedix TherapeuticsNCT06714864

Phase 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physica…

Long COVIDSars-CoV-2 InfectionCoronavirus Infections+1 more

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of inv…

Invasive Mould Infection

Estimated

~$10 – $8,750

Elion Therapeutics, Inc.NCT07215273